Health Care Drug Lenvatinib CAS 417716-92-8 for Thyroid Cancer Treatment
Quick Details:
Product name:Lenvatinib (E7080);Lenvima
Synonyms:4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide
CAS:417716-92-8
MF:C21H19ClN4O4
MW:426.85
Purity:99.3% minÂ
Appearance:White powder
MOQ:10g
Grade:Pharmaceutical Grade
Deliver methods:By express
Deliver time:About 5 days
Pharmacologic Category:Antineoplastic Agent, Tyrosine Kinase Inhibitor;Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor
COA:
Â
Product name
 Lenvatinib
CASÂ No.
 417716-92-8
Outer Packing
 100G
Production date
 2017-03-15
Shelf life
 2018-03-15
Standard adopted
 ENTERPRISE STANDARD
Items of analysis
Â
Specification
Â
Results
Â
DESCRIPTION
Light red to off-white solid
Light red solid
IDENTIFICATION
H-NMR;HPLC retention time
Conforms
ASSAY
98.0%Â Min
99.79%
TOTLEÂ IMPURITY
2.0%Max
0.21%
MAXIMUMÂ SINGLEÂ IMPURITY
0.2%MAX
0.07%
Conclusion
Â
Qualified
Â
History of Lenvatinib:
A phase I clinical trial in cancer patients was performed in 2006.A phase III trial treating thyroid cancer patients started in March 2011.
Lenvatinib was granted orphan drug status for treatment of various types of thyroid cancer that do not respond to radioiodine in the US and Japan in 2012 and in Europe in 2013.
In February 2015, the U.S. FDA approved lenvatinib for treatment of progressive, radioiodine refractory differentiated thyroid cancer.In May 2015, European Medicines Agency (EMA) approved the drug for the same indication.
In May 2016, the FDA approved it (in combination with everolimus) for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy.
What is Lenvatinib:
Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. Lenvatinib is used for the treatment of differentiated thyroid cancer that is either locally recurrent ormetastatic, progressive, and did not respond to treatment with radioactive iodine (radioiodine).LENVATINIB is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat thyroid cancer and kidney cancer. Compare kinase inhibitors.
How it works:
This medication is used to treat kidney or thyroid cancer. Lenvatinib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by slowing or stopping the growth of cancer cells.
Uses of Lenvatinib:
Lenvatinib is a prescription medication used to treat people with differentiatedthyroid cancer (DTC, a type of thyroid cancer) that can no longer be treated with radioactive iodine and is progressing.
Lenvima is also used in combination with everolimus in patients with advanced renal cell carcinoma who had previously received an anti-angiogenic therapy.
This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.
Where should I store this drug?
Keep out of the reach of children.
Store between 20 and 25 degrees C (68 and 77 degrees F). Throw away any unused medicine after the expiration date.
Our Advantages:
1. High quality with competitive price:
1)Standard: Enterprise Standard
2)All Purity¡Ã99%
3)We are manufacturer and can provide high quality products with factory price.
2. Fast and safe delivery
1)Parcel can be sent out in 24 hours after payment. Tracking number available
2)Secure and discreet shipment. Various transportation methods for your choice.
3)Customs pass rate ¡Ã99%
4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.
3. We have clients throughout the world.
1)Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2)Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.
3) High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.
Thank you and welcome your inquiry!
Â